Table 4.
Application of different types of aptamosomes loaded with specific drugs and liganded with varied aptamers
| S. no. | Aptamer | Drug used | Application of aptamosome | References |
|---|---|---|---|---|
| 1 | DNA (sgc8) | FITC-dextran | Used against CEM-CCRF acute leukemia cells targeting the protein tyrosine kinase receptor | Kang et al. (2010) |
| 2 | DNA (AraHH001) | Anti-angiogenesis drugs | Used against mouse tumor endothelial cells (mTEC) cells | Ara et al. (2012) |
| 3 | DNA (anti-PMSA) | doxorubicin | PMSA+ cell line (LNCaP), a mouse model of xenograft human prostate cancer | Baek et al. (2014) |
| 4 | DNA (AS1411) | siRNA | B-Raf oncoproteins for the treatment of malignant melanoma | Li et al. (2014a, b) |
| 5 | RNA aptamer | siRNA | Human transferrin expressing cells | Wilner et al. (2012) |
| 6 | RNA (Apt1) | siRNA | CD44+ receptor cancer cell line, (MDA-MB-231 breast cancer cells and A549 lung cancer cells) | Alshaer et al. (2015) |
| 7 | DNA (AS1411) | Doxorubicin and ammonium bicarbonate | Breast cancer cells (MCF-7/MDR) | Liao et al. (2015) |
| 8 | DNA (AS1411) | Doxorubicin | MDA-MB 231 breast cancer cell line | Zhang et al. (2015a, b, c) |
| 9 | AS1411 and Anti MUC-1 (S2.2) | Docetaxel and ammonium chloride | Dual targeting and tumor suppression | Zhao et al. (2017) |
CEM-CCRF leukemia lymphoblasts, PMSA prostate-specific membrane antigen, LNCaP androgen-sensitive human prostate adenocarcinoma cells, siRNA small interfering RNA